clinical robustness of csf ptau/aβ42 ratio for alzheimer’s disease diagnosis
Published 1 year ago • 472 plays • Length 5:21Download video MP4
Download video MP3
Similar videos
-
2:41
csf biomarkers for the early diagnosis of alzheimer’s disease
-
1:06
cerebrospinal fluid (csf) and imaging biomarkers for the differential diagnosis of dementia
-
1:23
csf tau as a biomarker of therapeutic effect
-
5:19
examining plasma vs. csf p-tau217 in preclinical and prodromal alzheimer’s disease
-
2:02
the role of phosphorylated tau in clinical trials
-
59:38
clinical trials, fad variants, and the etiology of alzheimer’s disease
-
2:17
alzheimer's | early detection of neuron loss | tau-c biomarker
-
5:01
noninvasive head probe for alzheimer's disease
-
1:14
research highlight: toxic tau aggregates determines type of dementia
-
1:00
what is alzheimer's disease? the importance of clinical trials
-
4:46
new subtype of alzheimer's disease defined by #mayoclinicfl neuroscientists - mayo clinic
-
14:25
"new therapeutic approaches to tau-related neurodegeneration" by dr. adam boxer
-
3:24
uqccr dementia and neuro mental health research unit
-
4:49
diagnostic utility of csf biomarkers in patients with rapidly progressive dementia
-
28:20
first phase 3 clinical trials targeting the tauopathy of alzheimer’s disease - claude wischik
-
3:09
the ‘big bang’ of alzheimer’s
-
28:47
what are clinical trials for alzheimer’s disease?
-
4:30
advances in alzheimer's disease research
-
1:35
neurology series- webinar 3 alzheimer's disease